




PARENTERAL DRUGS (INDIA) LTD.



Date: 14.05.2011

To
National Stock Exchange of India Limited
Exchange Plaza,
Plot No.C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai-400 051

Sub: Submission of Unaudited Financial Results for the quarter ended 31st March, 2011

Dear Sir,

Please find enclosed Unaudited Consolidated as well as Standalone Financial results for the quarter ended on 31st March, 2011.

This is for the information of the Exchange and members thereof.

You are requested to take the same on record.

Thanking You
Yours Sincerely
For Parenteral Drugs (India) Limited

Archana Agar
Company Secretary

Encl.: a/a

PARENTERAL DRUGS (INDIA) LIMITED

REGD. OFFICE : 340, LAXMI PLAZA, LAXMI INDUSTRIAL ESTATE, NEW LINK ROAD, MUMBAI - 400 053

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED ON 31ST MARCH, 2011

(Rs. In Lacs)

Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current Period	For the Year ended
	31-03-2011 (Unaudited)	31-03-2010 (Unaudited)	31-03-2011 (Unaudited)	31-03-2010 (Audited)
Net Sales/ Income from Operations	5726.43	11156.05	49973.28	41445.43
Other operating Income	16.38	17.61	96.21	186.52
Total Income	5742.81	11173.66	50069.49	41631.95
Expenditure				
- Increase / Decrease in stock in trade and work in progress	754.69	-38.05	-348.25	-59.22
- Consumption of raw materials	4006.55	5382.99	26341.43	22809.84
- Employees cost	545.17	405.14	2056.97	1395.16
- Depreciation	281.00	188.00	973.00	902.97
- Other Expenditure	4342.11	3515.08	17044.01	10862.04
Total	9929.52	9453.16	46067.16	35910.79
Profit from Operations before Other income ,Interest and Exceptional Items	-4186.71	1720.50	4002.33	5721.16
Other Income	0	0	0	0
Profit before Interest and Exceptional Items	-4186.71	1720.50	4002.33	5721.16
Interest	964.66	458.04	2763.15	1748.16
Profit after Interest but before Exceptional Items	-5151.37	1262.46	1239.18	3973.00
Exceptional Items	0	0	0	0
Profit from ordinary activities before tax	-5151.37	1262.46	1239.18	3973.00
Tax Expense	17.15	339.62	586.82	928.61
Net Profit from Ordinary Activities after Tax	-5168.52	922.84	652.35	3044.39
Extraordinary Items	0	0	0	0
Net Profit for the period after extra ordinary items	-5168.52	922.84	652.35	3044.39
Paid up equity share capital (Face value of Rs.10 per share)	2586.68	1940.00	2586.68	1940.00
Reserves excluding Revaluation Reserves				29625.76
Earnings Per Share (EPS)				
a. Basic EPS	-19.98	4.76	2.52	16.11
b. Diluted EPS	-19.98	4.76	2.52	16.11
Public Shareholding				
- Number of Shares	7974924	5958690	7974924	5958690
- Percentage of Shareholding	30.71%	30.71%	30.71%	30.71%
Promoters and Promoters group Shareholding				
a) Pledged/Encumbered				
- Number of Shares	2721600	2721600	2721600	2721600
- % of Shares of total shareholding of promoters	15.16%	20.25%	15.16%	20.25%
- % of Shares of total nominal capital	10.52%	14.03%	10.52%	14.03%
b) Non-encumbered				
- Number of Shares	15200307	10719833	15200307	10719833
- % of Shares of total shareholding of promoters	84.81%	79.75%	84.81%	79.75%
- % of Shares of total nominal capital	58.76%	55.26%	58.76%	55.26%

NOTES :

- The above consolidated unaudited financial results are reviewed by the audit committee at the meeting held on 14.05.2011 and thereafter taken on record by the Board of Directors at their meeting held on 14.05.2011.
- The Company is engaged in the Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS - 17).
- The above financial results have been subjected to a limited review by the Statutory Auditors.
- Figures for the earlier periods have been re-grouped / re-arranged where ever necessary.
- The Standalone results have been filed with the Stock Exchnage (s) as additional information along with the consolidated results, as per the requirement of clause 41 of the Listing Agreement.
- Standalone information:-

(Rs. In Lacs)

Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	For the Year ended
	31-03-2011 (Unaudited)	31-03-2010 (Unaudited)	31-03-2011 (Unaudited)	31-03-2010 (Audited)
Total Income	3888.73	9669.14	39723.23	33862.09
Profit Before Tax	-3768.12	1160.72	1356.81	3504.75
Profit After Tax	-3785.12	850.90	886.40	2728.97

7. Details of Investors complaints for the quarter ended 31 st March, 2011

Unresolved at the beginning of the quarter - Nil, Received during the quarter - 26, Disposed off during the quarter-26
Unresolved at the end of the quarter - Nil

FOR AND ON BEHALE OF THE BOARD


VINOD KUMAR GUPTA
MANAGING DIRECTOR

Place : Indore (M. P.)
Date : 14 th May, 2011

PARENTERAL DRUGS (INDIA) LIMITED
REGD. OFFICE : 340, LAXMI PLAZA, LAXMI INDUSTRIAL ESTATE, NEW LINK ROAD, MUMBAI - 400 053


UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER ENDED ON 31ST MARCH, 2011

STANDALONE			(Rs. in Lacs)	
Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current Period	For the Year ended
	31-03-2011 (Unaudited)	31-03-2010 (Unaudited)	31-03-2011 (Unaudited)	31-03-2010 (Audited)
Net Sales/ Income from Operations	3876.38	9654.18	39665.23	33728.21
Other operating Income	12.35	14.96	58.00	133.88
Total Income	3888.73	9669.14	39723.23	33862.09
Expenditure				
- Increase / Decrease in stock in trade and work in progress	252.83	-25.18	-515.62	18.69
- Consumption of raw materials	2604.15	4634.01	20267.91	18483.22
- Employees cost	455.17	316.17	1552.20	1073.34
- Depreciation	247.00	150.00	838.00	766.61
- Other Expenditure	3351.71	3047.25	13940.40	8635.22
Total	6910.85	8122.24	36082.88	28977.08
Profit from Operations before Other Income ,Interest and Exceptional Items	-3022.12	1546.90	3640.35	4885.01
Other Income	0	0	0	0
Profit before Interest and Exceptional Items	-3022.12	1546.90	3640.35	4885.01
Interest	746.00	386.18	2283.54	1380.26
Profit after Interest but before Exceptional Items	-3768.12	1160.72	1356.81	3504.75
Exceptional Items	0	0	0	0
Profit from ordinary activities before tax	-3768.12	1160.72	1356.81	3504.75
Tax Expense	17.00	309.82	470.41	775.78
Net Profit from Ordinary Activities after Tax	-3785.12	850.90	886.40	2728.97
Extraordinary Items	0	0	0	0
Net Profit for the period after extra ordinary items	-3785.12	850.90	886.40	2728.97
Paid up equity share capital (Face value of Rs.10 per share)	2586.68	1940.00	2586.68	1940.00
Reserves excluding Revaluation Reserves				28755.26
Earnings Per Share (EPS)				
a. Basic EPS	-14.63	4.39	3.43	14.44
b. Diluted EPS	-14.63	4.39	3.43	14.44
Public Shareholding				
- Number of Shares	7944924	5958690	7944924	5958690
- Percentage of Shareholding	30.71%	30.71%	30.71%	30.71%
Promoters and Promoters group Shareholding				
a) Pledged/Encumbered				
- Number of Shares	2721600	2721600	2721600	2721600
- % of Shares of total shareholding of promoters	15.18%	20.25%	15.18%	20.25%
- % of Shares of total nominal capital	10.52%	14.03%	10.52%	14.03%
b) Non-encumbered				
- Number of Shares	15200307	10719833	15200307	10719833
- % of Shares of total shareholding of promoters	84.81%	79.75%	84.81%	79.75%
- % of Shares of total nominal capital	58.76%	55.26%	58.76%	55.26%

NOTES :

- The above results are reviewed by the audit committee at the meeting held on 14.05.2011 and thereafter taken on record by the Board of Directors at their meeting held on 14.05.2011.
- The Company is engaged in the Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS - 17).
- The above financial results have been subjected to a limited review by the Statutory Auditors.
- Figures for the earlier periods have been re-grouped / re-arranged where ever necessary.
- The company has opted to furnish consolidated financial results in term of Clause 41(e) (i) of Listing Agreement and the same are being furnished to the Stock Exchange separately.
- Details of Investors complaints for the quarter ended 31st March, 2011
Unresolved at the beginning of the quarter - Nil, Received during the quarter - 26, Disposed off during the quarter-26
Unresolved at the end of the quarter - Nil

FOR AND ON BEHALF OF THE BOARD


VINOD KUMAR GUPTA
MANAGING DIRECTOR

Place : Indore (M. P.)
Date : 14 th May , 2011